Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia 4Vomiting 3Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, B-Cell 3Hodgkin Disease 3Breast Neoplasms 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Hairy Cell 2Kidney Neoplasms 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma in Situ 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Pemetrexed 12Cisplatin 11pembrolizumab 8Carboplatin 6Ipilimumab 5Nivolumab 4LMB-100 4durvalumab 3Gemcitabine 3tremelimumab 2tazemetostat 2anetumab ravtansine 2Vinorelbine 2Plicamycin 2Dexamethasone 2Cyclophosphamide 2Bevacizumab 2vandetanib 1tocilizumab 1spartalizumab 1ribociclib 1rebastinib 1pevonedistat 1olaparib 1niraparib 1nintedanib 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Mesothelioma × Diphenhydramine × Clear all
NCT04840615 2024-02-02

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
2 enrolled 14 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡